Share
Services
October 01, 2013
London, UK
May 14, 2013
Frankfurt, Germany
May 17, 2013
Frankfurt, Germany
June 11, 2014
London, UK
Fresenius SE & Co KGaA will be included in the EURO STOXX 50 blue-chip index on September 21, 2015. The index update was announced by the Deutsche Börse subsidiary STOXX after the close of trading on Monday night. The EURO STOXX 50 index tracks the share price development of 50 large publicly traded companies, representing various economic sectors, from twelve Eurozone countries.
Fresenius joined Germany’s blue-chip DAX index in March 2009, and has continued to post strong growth since then. Group sales almost doubled from €12.3 billion in 2008 to €23.2 billion in 2014. Over the same period, adjusted Group net income increased from €450 million to €1.086 billion.
Fresenius, which has more than 220,000 employees worldwide, has ambitious growth targets for this year. Group sales for 2015 are expected to rise by 8% to 10% in constant currency, while adjusted Group net income is forecasted to increase by approximately 18% to 21% in constant currency.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius Medical Care has released a new single-use adsorber for the treatment of IgE (ImmunoglobulinE)-mediated diseases in the European market.
Latest epidemiological data shows that IgE-mediated diseases affect more than 25 percent of the world’s population. Of this group, an estimated 10 percent suffer from severe allergic symptoms such as asthma and atopic dermatitis. The new adsorber, called IgEnio®, is intended to provide a therapy option for these patients.
IgEnio® complements the growing portfolio of Fresenius Medical Care’s Therapeutic Apheresis business, which already offers adsorbers targeting the reduction of ImmunoglobulinG (a therapy for autoimmune diseases) and the removal of other, specific pathogens.
IgEnio® was developed on the basis of Fresenius Medical Care’s longstanding expertise in extracorporeal treatments, and represents a further step in the strategic expansion of this important therapy field. IgEnio® was co-developed with Biomay AG, a global leader in allergy immunotherapy products, based in Vienna.
The clinical results of IgEnio® were presented for the first time at a scientific congress in Barcelona in June. IgEnio® will be introduced in selected markets – France, Germany, Italy, Spain and the United Kingdom – in the course of 2015. Fresenius Medical Care will continue the rollout within its Europe, Middle East and Africa region.
The IgE synthesis pathway and the IgE-mediated allergic/inflammatory pathway are important targets in intervening in the pathological processes of allergy. IgEnio® is a single-use, single-pass adsorber that selectively decreases IgE levels in the plasma. The first clinical trial of IgEnio®, called ESPIRA, included patients with severe allergic asthma not sufficiently controlled by inhaled steroids and other medications. These patients, who have high IgE levels in their plasma, currently have very limited treatment options.
The primary end point of the ESPIRA study was to reduce IgE levels by more than 50 percent over the treatment period and to demonstrate safe application in clinical practice. Within the study, patients underwent nine apheresis treatments with IgEnio®, with each treatment lasting for approximately four hours. As a result of the treatments, a highly significant reduction of more than 80 percent in plasma IgE was observed (p<0.001). For highly allergic patients in the ESPIRA study setting, lgEnio® was safe and well tolerated.
To strengthen the scientific evidence base and to create more clinical expertise, Fresenius Medical Care will conduct further clinical investigations in the coming years.
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius expects a significant 2015 dividend increase, resulting from the forecasted 2015 net income growth applied to the company’s dividend policy. After raising guidance twice this year, Fresenius is forecasting 2015 net income growth of 18% to 21% in constant currency. In addition, the company expects a significant positive currency effect. 2015 dividend growth is therefore expected to clearly exceed 20%. This will mark the company’s 23rd consecutive year of dividend increases.
Ulf Mark Schneider, CEO of Fresenius, said: “Fresenius’ business model is non-cyclical and we confirm our guidance for 2015. Our expectations for 2016 are also very positive, even in light of current concerns about the global economy.”
In February 2014, Fresenius announced a net income target of €1.4 to €1.5 billion for 2017. Assuming stable exchange rates from here, Fresenius will reach that target this year – two years ahead of schedule. Even if the currency contribution declines in the coming months, the company will come very close.
“We therefore plan to provide a new mid-term target in February 2016 to guide investors’ expectations regarding the company’s future growth ambitions,” Schneider said.
Fresenius will announce its Q3 2015 results on October 29, 2015.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
A nurse prepares an intravenously administered (I.V.) drug. Fresenius Kabi is a leading supplier of I.V. generic drugs. Seen in the background are Agilia series infusion pumps for the administration of I.V. drugs.
